RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
CASI Pharma, a US-China company, announced a $48.5 private placement that will be used to in-license additional drugs and obtain approvals of its current portfolio of drug candidates. In early 2018, CASI acquired global rights to a portfolio of 29 generic drugs from Sandoz with abbreviated ANDAs submitted in the US. CASI said it would choose some of the generics for China development. The company also has three drugs in-licensed from Spectrum that are currently in China trials. CASI is headquartered in Maryland with R&D operations in Beijing.
Source: China Biotoday
